AR124419A1 - Células seguras invisibles para el sistema inmunitario - Google Patents

Células seguras invisibles para el sistema inmunitario

Info

Publication number
AR124419A1
AR124419A1 ARP210103566A ARP210103566A AR124419A1 AR 124419 A1 AR124419 A1 AR 124419A1 AR P210103566 A ARP210103566 A AR P210103566A AR P210103566 A ARP210103566 A AR P210103566A AR 124419 A1 AR124419 A1 AR 124419A1
Authority
AR
Argentina
Prior art keywords
mammalian cell
genes
hsv
immune system
gene
Prior art date
Application number
ARP210103566A
Other languages
English (en)
Spanish (es)
Inventor
Jay Chaplin
Ulrik Dhn
Thomas Frogne
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR124419A1 publication Critical patent/AR124419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP210103566A 2020-12-18 2021-12-17 Células seguras invisibles para el sistema inmunitario AR124419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20215272 2020-12-18

Publications (1)

Publication Number Publication Date
AR124419A1 true AR124419A1 (es) 2023-03-29

Family

ID=73855659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103566A AR124419A1 (es) 2020-12-18 2021-12-17 Células seguras invisibles para el sistema inmunitario

Country Status (3)

Country Link
AR (1) AR124419A1 (zh)
TW (1) TW202242095A (zh)
WO (1) WO2022129472A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008979A1 (en) 2022-09-30 2024-01-11 Novo Nordisk A/S A sirp-alpha binding chimeric protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456374A4 (en) 2001-11-26 2005-08-17 Advanced Cell Tech Inc METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS
IL162663A0 (en) 2001-12-28 2005-11-20 Cellartis Ab A method for the establishment of apluripotent human blastocyst-derived stem cell line
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
WO2007042225A2 (en) 2005-10-07 2007-04-19 Cellartis Ab A method for obtaining a xeno-free hbs cell line
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
JP2014513948A (ja) 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞
DK3039122T3 (da) 2013-08-30 2019-09-30 Novo Nordisk As Generering af endokrine progenitorceller fra humane pluripotente stamceller under anvendelse af små molekyler
CN115806940A (zh) * 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
EP3420073B1 (en) 2016-02-24 2023-11-08 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US20190048060A1 (en) 2017-08-08 2019-02-14 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
JP2021526838A (ja) * 2018-06-12 2021-10-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 幹細胞の操作によるｉｎｋｔ細胞に基づく既製の細胞療法
WO2020012033A1 (en) * 2018-07-13 2020-01-16 Lothar Germeroth Non-immunogenic engineered tissue and methods of producing and using the same
EP3833682B1 (en) * 2018-10-01 2022-08-17 Caribou Biosciences, Inc. Suicide module compositions and methods

Also Published As

Publication number Publication date
WO2022129472A1 (en) 2022-06-23
TW202242095A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
EA201991849A1 (ru) Система и способ редактирования генома
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
Taylor et al. Heterogeneity in the differentiation and function of memory B cells
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
BR112019008560A2 (pt) célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação
Sanz et al. Biosynthesis of GDP-fucose and other sugar nucleotides in the blood stages of Plasmodium falciparum
AR124419A1 (es) Células seguras invisibles para el sistema inmunitario
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
CL2017000528A1 (es) Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción
BR112015027996A2 (pt) organoides compreendendo células renais isoladas e suas utilizações
BR112016016937A2 (pt) Célula adaptada a suspensão isolada transduzida ou transfectada com um ácido nucleico heterólogo, porção ligada a membrana, porção ligada a membrana da célula, pluralidade de células adaptadas a suspensão isoladas, porção ligada à membrana de uma célula adaptada a suspensão isolada, partículas semelhantes a vírus ou vírus produzidas pela célula, vírus isolado, partícula semelhante a vírus isolada, pluralidade de vírus isolados, pluralidade de partículas semelhantes a vírus isoladas, ácido nucleico recombinante, células adaptadas a suspensão isoladas, célula adaptada a suspensão isolada transduzida ou transfectada com um ácido nucleico heterólogo, célula adaptada a suspensão isolada transduzida por ou transfectada com um vírus, ácido nucleico recombinante, método de identificação de um epítopo de célula t
BR112016007919A2 (pt) vacinas atenuadas vivas
CY1112351T1 (el) ΛΗΨΗ ΚΥΤΤΑΡΩΝ Tr1, ΕΙΔΙΚΩΝ ΓΙΑ ΑΝΤΙΓΟΝΑ ΤΡΟΦΙΜΟΥ Ή ΓΙΑ ΑΥΤΟΑΝΤΙΓΟΝΑ ΑΠΟ ΕΝΑΝ ΠΛΗΘΥΣΜΟ ΛΕΥΚΟΚΥΤΤΑΡΩΝ PBMC
BR112021014645A2 (pt) Método de edição de genes
AR109451A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
BR112016012229A2 (pt) métodos de produção de polipeptídeos
Braid et al. Engineered mesenchymal cells improve passive immune protection against lethal Venezuelan equine encephalitis virus exposure
ECSP22051779A (es) Métodos para mejorar el cultivo celular con proteínas específicas de cada especie o específicas de cada género y las aplicaciones de los mismos
CN104131018A (zh) 一种细胞内蛋白自诱导表达的方法
Hjelm et al. Autotransporter-based antigen display in bacterial ghosts
CY1122993T1 (el) Μεθοδος παραγωγης για πολυδυναμα βλαστοκυτταρα που εχουν αντιγονο-ειδικο γονιδιο υποδοχεα τ κυτταρων
EA202191360A1 (ru) Усовершенствованное получение рибофлавина
CL2011003104A1 (es) Metodo para la elaboracion de acidos grasos no saturados, basado en el cultivo de una celula que expresa un polipeptido heterologo con actividad esaturasa/enoil-coa reductasa celula huesped, complejo elongasa que comprende dicho polipeptido y uso de la misma.
MY195280A (en) Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability

Legal Events

Date Code Title Description
FB Suspension of granting procedure